Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.5
Journals
Cancers
Special Issues
The Prevention and Treatment of Prostate Cancer
cancers-logo
Submit to Cancers Review for Cancers Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

The Prevention and Treatment of Prostate Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (31 March 2025) | Viewed by 4211

Special Issue Editors

Dr. Ning Wang

E-Mail Website
Guest Editor
1. Leicester Cancer Research Centre, University of Leicester, Leicester, UK
2. Division of Clinical Medicine, University of Sheffield, Sheffield, UK
Interests: discovery research in cancer prevention and treatment, particularly in cancer induced bone disease
Dr. Kirsty Hodgson

E-Mail Website
Guest Editor
Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK
Interests: prostate cancer; glycobiology; bone metastasis

Special Issue Information

Dear Colleagues,

Prostate cancer is the second most commonly diagnosed cancer and the fifth leading cause of cancer-related death in men worldwide, resulting in 375,000 deaths annually. This number is predicted to rise by 85%, reaching almost 700,000 worldwide by 2040. Therefore, identifying innovative and effective targets for preventing and treating prostate cancer is of great clinical need.

Recent advances in prostate cancer treatment over the past five years have focused on improving precision medicine, immunotherapy, and new drug developments, such as PARP inhibitors, radiopharmaceuticals, and next-generation anti-androgens. These advancements reflect a trend toward more personalized, targeted, and effective treatments for prostate cancer, improving both survival rates and quality of life for patients.

We are pleased to invite you to contribute to this Special Issue of Cancers titled “The Prevention and Treatment of Prostate Cancer”. This Special Issue will promote studies exploring the mechanisms controlling prostate cancer initiation and progression to open new avenues for identifying novel therapeutic targets in fighting this deadly disease.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

  • Prostate cancer prevention research on genetic and epigenetic risk factors, lifestyle and diet, chemoprevention, chronic inflammation and infections, and microbiome;
  • Novel mechanisms controlling prostate cancer tumorigenicity and metastasis;
  • Innovative methods or model systems used to investigate prostate cancer progression in clinical and preclinical studies;
  • Advances in prostate cancer precision medicine, drug resistance, immunotherapy, radiopharmaceuticals, and combination therapies

We look forward to receiving your contributions.

Dr. Ning Wang
Dr. Kirsty Hodgson
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prostate cancer
  • prevention
  • metastasis
  • drug resistance
  • tumor microenvironment
  • novel therapies
  • immunotherapy
  • androgen
  • hormone therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 919 KiB  
Article
Health Professionals’ Perceptions about Prostate Cancer—A Focus Group Study
by Catarina Leitão, Marta Estrela, Luís Monteiro, Margarida Fardilha, Maria Teresa Herdeiro and Fátima Roque
Cancers 2024, 16(17), 3005; https://doi.org/10.3390/cancers16173005 - 29 Aug 2024
Viewed by 1669
Abstract
Prostate cancer (PCa) accounts for 20% of new cancer cases and 10.5% of cancer-associated mortality in Portugal. Associated risk factors include advanced age, family history, genetic alterations, and race/ethnicity. However, the role of lifestyle factors is often underestimated. To explore health professionals’ perceptions [...] Read more.
Prostate cancer (PCa) accounts for 20% of new cancer cases and 10.5% of cancer-associated mortality in Portugal. Associated risk factors include advanced age, family history, genetic alterations, and race/ethnicity. However, the role of lifestyle factors is often underestimated. To explore health professionals’ perceptions of PCa risk factors, a qualitative study with three focus groups (FG), with a total of twenty-one general practitioners and urologists, was conducted via videoconference between February and April 2023. Seven themes emerged, including general perceptions of PCa; PCa risk factors; nutritional impact; the role of physical activity; alcohol consumption and smoking; sexual activity and sexually transmitted diseases roles in PCa; and screening, diagnosis, and treatment methods. Despite agreeing that healthy lifestyles could promote better PCa outcomes and quality of life, participants did not specify any lifestyle factors that could promote or prevent this disease, posing challenges to lifestyle changes, particularly among older adults. Non-invasive screening methods, such as biomarkers and alternative treatments, are crucial for future research. This study underscores the need for further investigation into the correlation of lifestyle factors with PCa and highlights the necessity of health professionals in encouraging their patients to adopt healthier lifestyles, while offering important insights into awareness, prevention, and alternative screening, diagnosis, and treatment methods, which could help reduce false positives and treatment side effects. Full article
(This article belongs to the Special Issue The Prevention and Treatment of Prostate Cancer)
►▼ Show Figures

Graphical abstract

16 pages, 7643 KiB  
Article
Sialylation Inhibition Can Partially Revert Acquired Resistance to Enzalutamide in Prostate Cancer Cells
by Emily Archer Goode, Margarita Orozco-Moreno, Kirsty Hodgson, Amirah Nabilah, Meera Murali, Ziqian Peng, Jona Merx, Emiel Rossing, Johan F. A. Pijnenborg, Thomas J. Boltje, Ning Wang, David J. Elliott and Jennifer Munkley
Cancers 2024, 16(17), 2953; https://doi.org/10.3390/cancers16172953 - 24 Aug 2024
Cited by 2 | Viewed by 2053
Abstract
Prostate cancer is a lethal solid malignancy and a leading cause of cancer-related deaths in males worldwide. Treatments, including radical prostatectomy, radiotherapy, and hormone therapy, are available and have improved patient survival; however, recurrence remains a huge clinical challenge. Enzalutamide is a second-generation [...] Read more.
Prostate cancer is a lethal solid malignancy and a leading cause of cancer-related deaths in males worldwide. Treatments, including radical prostatectomy, radiotherapy, and hormone therapy, are available and have improved patient survival; however, recurrence remains a huge clinical challenge. Enzalutamide is a second-generation androgen receptor antagonist that is used to treat castrate-resistant prostate cancer. Among patients who initially respond to enzalutamide, virtually all acquire secondary resistance, and an improved understanding of the mechanisms involved is urgently needed. Aberrant glycosylation, and, in particular, alterations to sialylated glycans, have been reported as mediators of therapy resistance in cancer, but a link between tumour-associated glycans and resistance to therapy in prostate cancer has not yet been investigated. Here, using cell line models, we show that prostate cancer cells with acquired resistance to enzalutamide therapy have an upregulation of the sialyltransferase ST6 beta-galactoside alpha-2,6-sialyltransferase 1 (ST6GAL1) and increased levels of α2,6-sialylated N-glycans. Furthermore, using the sialyltransferase inhibitor P-SiaFNEtoc, we discover that acquired resistance to enzalutamide can be partially reversed by combining enzalutamide therapy with sialic acid blockade. Our findings identify a potential role for ST6GAL1-mediated aberrant sialylation in acquired resistance to enzalutamide therapy for prostate cancer and suggest that sialic acid blockade in combination with enzalutamide may represent a novel therapeutic approach in patients with advanced disease. Our study also highlights the potential to bridge the fields of cancer biology and glycobiology to develop novel combination therapies for prostate cancer. Full article
(This article belongs to the Special Issue The Prevention and Treatment of Prostate Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop